DeepMatter Group Plc (AIM: DMTR) (“DeepMatter” the “Company” or the “Group”), the international digital chemistry data company , today announces a placing and subscription to raise gross proceeds o f
DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), the international digital chemistry data company, has signed a contract with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), based in Hyderabad, India, for
The following Q&A comes from the recent DeepMatter Group Plc Half Year Results Webinar
DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), which focuses on digitalising chemistry, announces that its CEO, Mark Warne, has been invited to chair the Industrial Advisory Board (IAB) at
AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC). It is now available for chronic kidney disease (CKD), in adults with or without type-2 diabetes (T2D), in the
DeepMatter collaborates with the University of Cambridge’s Innovation Centre in Digital Molecular Technologies
DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is pleased to announce that Bryn Roberts has been appointed to the Board as Non-Executive Director with effect from 1
Deltex has published an update on trading for the half-year ended 30 June 2021. While the shock of COVID-19 and its associated hit on levels of elective surgery now appears
FastForward Innovations Ltd, (AIM:FFWD) the listed investor focused on fast-growing and industry leading businesses, is pleased to announce that it has participated in the £2.1 million issuance of Convertible Loan
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused
Byotrol (AIM:BYOT) the specialist infection and prevention control company, is pleased to announce an update on trading.
